Abstract
China has been investing heavily in biotechnology to increase agricultural productivity. While a number of Chinese developed GM crops have cleared the required scientific hurdles - some more than a decade ago - commercialization has not been approved. The regulatory regime for GMOs in China is relatively less well understood than that of the US or the EU. This paper provides a systematic overview of China's regulatory regime, R&D investment and delayed commercialization decisions on biotechnology over the last 40 years and draws some conclusions regarding the likelihood of the commercialization for major GM crops in the future.